This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05372757
Recruitment Status : Not yet recruiting
First Posted : May 13, 2022
Last Update Posted : April 20, 2023
Sponsor:
Information provided by (Responsible Party):
Taufiek Rajab, MD, Medical University of South Carolina

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The long-term goal of this research initiative is to develop a new valve replacement option for neonates, infants and young children. The central hypothesis is that transplantation of a freshly isolated heart valve will be associated with superior outcomes compared to currently available options, including preserved cadaver valves, bioprosthetic tissue valves, or mechanical valves. This new operation has been named "partial heart transplantation".

The proposed study is a single-center, nonrandomized single arm pilot trial of "partial heart transplantation" in neonates, infants and young children who require semilunar heart valve replacement. This "first in man" trial seeks to determine whether valve replacement using partial heart transplant is feasible and safe. Primary aims are survival one year and five years following the procedure. The hypothesis is that, when compared to historical controls who have undergone homograft valve replacement, those undergoing partial heart transplantation will have equal or superior survival one year and five years following the procedure. Secondary aims are to assess growth and function of the transplanted valve. The hypothesis is that when compared to historical controls who have undergone conventional valve replacement, those undergoing partial heart transplantation will have valve growth that corresponds with somatic growth and superior valve function 1 year following the procedure. Up to five patients will be enrolled in this trial over three years.


Condition or disease Intervention/treatment Phase
Semilunar Heart Valve Replacement Procedure: Partial Heart Transplantation Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction
Estimated Study Start Date : April 2023
Estimated Primary Completion Date : April 2027
Estimated Study Completion Date : September 2040

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Partial Heart Transplantation Arm Procedure: Partial Heart Transplantation
The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The ability to perform the new operation in at least 1 patient per year for 3 years (averaged) after enrollment opens. [ Time Frame: Duration of the study (3 years after enrollment opens). ]
    This is how feasibility will be measured. This will be answered as "yes" or "no".

  2. Number of participants who achieve survival. [ Time Frame: 6 months after all 5 subjects have been enrolled. ]
    Safety will primarily be defined as patient survival or re-operation or transcatheter reintervention on the transplanted valve at 6-month intervals, starting 6 months after the first subject undergoes a valve transplant, and continuing until 1 year after all 5 subjected have been enrolled.

  3. Number of participants who achieve survival. [ Time Frame: 1 year after all 5 subjects have been enrolled. ]
    Safety will primarily be defined as patient survival or re-operation or transcatheter reintervention on the transplanted valve at 6-month intervals, starting 6 months after the first subject undergoes a valve transplant, and continuing until 1 year after all 5 subjected have been enrolled.


Secondary Outcome Measures :
  1. Valve annulus growth. [ Time Frame: Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first. ]
    The valve annulus diameter will be measured using echocardiography in 2 planes at baseline (i.e., during postoperative hospitalization 5-10 days after surgery) and every 6 months following the operation. It is expected that the valve annulus diameter Z score will be relatively unchanged over time, which would reflect an absolute increase in valve annulus growth corresponding with an increase in body surface area.

  2. The level of valve stenosis. [ Time Frame: Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first. ]
    Mean valve stenosis will be assessed by transthoracic echocardiogram using pulse Doppler every 6 months following the operation.

  3. The level of valve regurgitation. [ Time Frame: Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first. ]
    Mean valve regurgitation will be assessed with color Doppler echocardiography.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Day to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children less than 2 years of age who are referred for a cardiac operation that involves a primary semilunar valve replacement or children less than 2 years of age who are referred for a cardiac operation involves an initial replacement of a previously placed prior homograft, bioprosthetic, or mechanical valve in the aortic or pulmonary position.
  • Deemed acceptable for partial heart transplantation based on the standard evaluation process used for orthotopic heart transplantation (see Appendix 1) Insurance approval.
  • Written informed consent of both parents/guardians; if there is only one parent/guardian, consent from that individual will be adequate.

Exclusion Criteria:

  • Absolute contraindications for orthotopic heart transplantation.
  • Severe bilateral long segment pulmonary arterial hypoplasia
  • Bilateral pulmonary vein stenosis
  • <34 weeks corrected gestational age
  • Persistent acidosis with a pH < 7.1
  • Diagnosis of immune deficiency.
  • Inability for the parent to understand English or Spanish.
  • Failure to pass the following psychosocial evaluation:
  • The candidate should reside within 4 hours traveling time from Medical University of South Carolina for a minimum of four to six months post-transplantation to assure careful follow-up
  • The candidate's family should be capable of long-term supportive care of the child and be able to support the medical needs of the child in follow-up
  • Parental (custodial) alcohol and/or substance abuse
  • Documented parental (custodial) child abuse or neglect
  • Parent (custodian) with cognitive/psychiatric impairment severe enough to limit comprehension of medical regimen
  • Infectious Disease Exclusion Criteria
  • Evidence of sepsis
  • Hepatitis B surface antigenemia
  • HIV positivity
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Taufiek Rajab, MD, Assistant Professor, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT05372757    
Other Study ID Numbers: 00114653
First Posted: May 13, 2022    Key Record Dates
Last Update Posted: April 20, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No